Johnson & Johnson's SPECTREM Study Shows TREMFYA® (Guselkumab) Significantly Clears Low BSA Plaque Psoriasis In Special Sites; Achieves Primary And Secondary Endpoints In Phase 3b Trial
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson's SPECTREM study reveals that TREMFYA® (Guselkumab) effectively clears low BSA plaque psoriasis in special sites, achieving primary and secondary endpoints in a Phase 3b trial. The company also launched a clinical image library to assist in decision-making for diverse skin tones.
October 25, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's TREMFYA® has shown significant efficacy in treating low BSA plaque psoriasis, achieving key endpoints in a Phase 3b trial. This could enhance the drug's market position and support its use in diverse populations.
The successful Phase 3b trial results for TREMFYA® indicate its effectiveness in treating psoriasis, which could lead to increased adoption and sales. The launch of a clinical image library further supports its use across diverse populations, potentially expanding its market reach.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90